Despite decades of research, including heavily funded Human Brain Project (EU) and BRAIN (NIH) initiatives, our understanding of the big picture of brain functions is still incomplete and insights on neuro-pathophysiological conditions and diseases (such as cerebral ischemia, glioma, epilepsy and depression) are very limited. This lack of knowledge inhibits our ability to provide the proper treatment of neurological conditions and meet this major societal challenge. It was estimated that there were 127 million Europeans living with a brain disorder and disease out of a population of 466 million. The total annual cost in healthcare of brain disorders in Europe was estimated in a range between €386 to 700 billion in 20101. The frequency of epilepsy alone in Europe in 2004 was 4.3-7.8 per 1,000, leading to an estimated total cost of €15.5 billion in 2010. This societal challenge call for an urgent action to develop better diagnostic tools and treatments, which require major technological and conceptual advances1. A major obstacle of previous and current initiatives on Neurotechnologies is a lack of interest in non-neuronal brain cells, called glia, which are as numerous as neurons.
ASTROTECH will create and develop the field of Glial Engineering, to provide a consistent range of tools to record, study, and manipulate astrocytes in the healthy and diseased brain.
ASTROTECH will train the next generation of brain scientists with the required skills in the supradisciplinary field of Glial Engineering.
ASTROTECH will provide knowledge and tools that will fill major gaps in our current understanding and provide unprecedented opportunities for seeking new ways to treat, cure, and even prevent brain disease such as epilepsy, glioma, ischemia and depression.
ASTROTECH ambition is to provide device and approaches that allow producing a revolutionary new dynamic picture of the brain to record, process, utilize, store, and retrieve vast quantities of information, and on how these processes are compromised in pathologies.The latter not only represent a crucial societal issue, but also substantially add to the public expenditure for medical and non-medical care of patients. The socio-economic impact resulting from a potential treatment of these pathologies, will be a very attractive challenge for the biopharmaceutical sector. Entrepreneurial initiatives coming from the new generation of experts and scientists will be equally considered.